Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6150MR)

This product GTTS-WQ6150MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6150MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15843MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ14065MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ11948MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ6376MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ4696MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ13952MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ11174MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW